It was special for our team to celebrate 50 years of impact with the National MPS Society at their Masquerade Gala! It was an evening filled with hope, honoring the progress and community of this incredible organization. Congratulations, National MPS Society, on this remarkable milestone!
REGENXBIO
Biotechnology Research
Rockville, Maryland 43,345 followers
Seeking to improve lives through the curative potential of gene therapy.
About us
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Locations
-
Primary
Get directions
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO
Updates
-
Today, we recognize World Sight Day — a global call to action in the fight against vision loss. At REGENXBIO, we’re dedicated to advancing potential new therapies for wet AMD and diabetic retinopathy, two leading causes of vision loss worldwide. On this day, and every day, we stand with the vision health community to raise awareness and support those impacted by vision-threatening diseases.
-
-
Join REGENXBIO at the American Academy of Ophthalmology annual meeting. Dr. Charles Wykoff will present interim results from the Phase II ALTITUDE® trial of sura-vec, an investigational gene therapy for the treatment of diabetic retinopathy. #AAO25 Learn more: https://lnkd.in/e5P3YkdY
-
-
Today, we announced the completion of enrollment in the ATMOSPHERE and ASCENT pivotal studies evaluating sura-vec (ABBV-RGX-314) in wet AMD using subretinal delivery. Enrolling over 1,200 participants, these trials represent the largest gene therapy program ever conducted. Learn more: https://lnkd.in/e_NC-sTF
-
-
REGENXBIO is proud to present at the Alliance for Regenerative Medicine’s Meeting on the Mesa. CEO Curran Simpson and Chief Strategy and Legal Officer Patrick Christmas will join fellow cell and gene therapy leaders focused on innovating and advancing this class of transformative medicines for patients. #CGMesa25
-
-
October is Blindness Awareness Month. We’re working to change the future of vision health by developing gene therapies with the potential to transform the standard of care for diseases like wet AMD and diabetic retinopathy. We’re proud to stand with the community to raise awareness and advocate for vision health.
-
-
Yesterday, we welcomed back Bob Stevens – MPS dad, passionate advocate, and CEO of MPS Society UK - to REGENXBIO. Bob met with our team, toured our Manufacturing Innovation Center, and shared meaningful reflections from his personal journey and leadership in advancing care for rare diseases. Thank you, Bob, for joining us!
-
-
Today, we announced an upcoming presentation from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 at the International Congress of the World Muscle Society. Learn more: https://lnkd.in/evKn8p6h
-
-
At our recent all-company meeting, we announced our CEO Award winner, Keith Webber! Keith has been with REGENXBIO for 9 years and has made tremendous contributions to our success—advancing our expertise in analytical methods and shaping our approach to analytical studies. Join us in celebrating Keith for this well-deserved recognition!
-
-
Thank you to Parent Project Muscular Dystrophy for hosting this past weekend’s PPMD Together meeting in Charlotte, NC! We enjoyed being with families, caregivers, advocates, and industry partners to share experiences and work toward creating better futures for everyone affected by Duchenne. Glad to be part of it!
-